NEW YORK, Dec 8 (Reuters) - U.S. Food and Drug Administration staff cited concerns on Tuesday with the design and analysis of clinical studies intended to support the effectiveness of Gilead Sciences Inc's (GILD.O) experimental cystic fibrosis drug.
NEW YORK, Dec 8 (Reuters) - U.S. Food and Drug Administration staff cited concerns on Tuesday with the design and analysis of clinical studies intended to support the effectiveness of Gilead Sciences Inc's (GILD.O) experimental cystic fibrosis drug.
